SLC6A2
Sodium-dependent noradrenaline transporter
As of the edition of 20 October 2026, SLC6A2 (sodium-dependent noradrenaline transporter, UniProt P23975) has 56 drugs tested at it and 80 companies on the list, 9 on route A and 16 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P23975
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 37
- Disease areas
- Mental health; Nervous system; Chemically induced; Bones, joints and muscles; Nutrition and metabolism; Cancer; Urinary and reproductive; Lungs and airways
- Registered trials of its drugs
- 1,627
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 36 |
| Active | 3 |
| Went quiet | 7 |
| Stopped | 6 |
| Withdrawn from market | 4 |
| Total | 56 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Methylphenidate | Marketed | Phase 4 | none listed |
| Duloxetine | Marketed | Phase 4 | none listed |
| Bupropion | Marketed | Phase 4 | none listed |
| Atomoxetine | Marketed | Phase 4 | none listed |
| Lisdexamfetamine | Marketed | Phase 4 | none listed |
| Tapentadol | Marketed | Phase 4 | Ends 2027 |
| Pseudoephedrine | Marketed | Phase 4 | none listed |
| Dextroamphetamine | Marketed | Phase 4 | none listed |
| Amphetamine | Marketed | Phase 4 | none listed |
| Phentermine | Marketed | Phase 4 | none listed |
| Milnacipran | Marketed | Phase 4 | none listed |
| Desipramine | Marketed | Phase 4 | none listed |
12 of 56 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 9 |
| Route B | 16 |
| Engaged | 18 |
| Undetermined | 37 |
| Total on the list | 80 |
The other 77 companies at SLC6A2
In the product80 companies in all; 77 are not named here, and no score is.
See the 80 companies at SLC6A2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.